Avid Bioservices, Inc. (CDMO) News
Filter CDMO News Items
CDMO News Results
|Loading, please wait...|
CDMO News Highlights
- For CDMO, its 30 day story count is now at 7.
- Over the past 23 days, the trend for CDMO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- AVID, AP and CELL are the most mentioned tickers in articles about CDMO.
Latest CDMO News From Around the Web
Below are the latest news stories about AVID BIOSERVICES INC that investors may wish to consider to help them evaluate CDMO as an investment opportunity.
On September 21, 2023, Director Joseph Carleone made a significant investment in Avid Bioservices Inc (NASDAQ:CDMO), purchasing 20,000 shares of the company.
Avid Bioservices, Inc. (NASDAQ:CDMO) Q1 2024 Earnings Call Transcript September 7, 2023 Avid Bioservices, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.04. Operator: Good day, ladies and gentlemen and welcome to the Avid Bioservices First Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call may be recorded. […]
Q1 2024 Avid Bioservices Inc Earnings Call
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 100% and 10.96%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
TUSTIN, Calif. (AP) — Avid Bioservices Inc. (CDMO) on Thursday reported a fiscal first-quarter loss of $2.1 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Tustin, California-based company said it had a loss of 3 cents. Avid Bioservices expects full-year revenue in the range of $145 million to $165 million.
-- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million -- -- Cell and Gene Therapy Facility Expansion Remains on Schedule for Opening by End of Calendar Q3 2023 -- TUSTIN, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manu
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023
TUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2024 on September 7, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members
In this article, we will take a look at the 11 most undervalued biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Undervalued Biotech Stocks to Buy According to Analysts. The M&A activity in the biotech industry […]
Laughing Water Capital, an investment management company, released its second-quarter 2023 investor letter. A copy of the same can be downloaded here. In the second quarter, investment in the fund returned 13.8%, net of all fees and expenses, compared to the SP500TR and the R2000 returns of 8.7% and 5.2%, respectively. The fund’s return so far […]
Avid Bioservices (NASDAQ: CDMO) hasn't been a very lively investment in recent days. According to data compiled by S&P Global Market Intelligence, the specialty healthcare company's stock was down 17% week to date as of early Friday morning. Avid Bioservices, a contract developer and manufacturer of biologics, released its fiscal 2023 fourth-quarter results after market hours on Wednesday.